Partnering with IMU

Partnering to advance immune-driven medicine. The hardest problems in medicine don't get solved alone.

Partnering with IMU

Partnering to advance immune-driven medicine. The hardest problems in medicine don't get solved alone.

Partnership is central to how we translate IMU’s technology into impact. By working closely with clinical, academic and industry leaders, we can apply our platform across the drug development process — from translational research through to clinical medicine — helping partners unlock new immune insights and advance better outcomes for patients.

John Baker PhD

Chief Executive Officer

Mario Cantero MBA

Co-founder & Chief Operating Officer

Join our mission

IMU partners with clinical research groups, pharmaceutical, biotech and diagnostics companies to identify, validate and deploy clinically actionable immune signatures across three connected areas:

Decoding

Decoding immunity in health and disease

● Discovery of novel immune signatures of disease ● Discovery of mechanistic insights into treatment success, resistance and toxicity ● Identification of new therapeutic targets and immune-driven pathways ● Identification of biomarkers for early diagnosis and disease endotyping ● Access to structured, annotated, multi-modal immune data for AI model training

Discovery

Improving drug discovery and development

● Prediction of likely responders and non-responders ● Patient stratification and selection to improve clinical trial outcomes ● Identification of biomarkers for study design and endpoint selection ● Prediction and monitoring of immune-related adverse events

Precision

Delivering immune driven precision medicine

● Development and delivery of biomarker-driven companion diagnostics ● Personalised drug selection, drug titration and patient monitoring ● Improved donor selection for transplantation